Financial investors show appetite for E.CIS Cosmetic The sheet-mask original equipment manufacturer's planned IPO fell through
이 기사는 2020년 02월 13일 08:00 더벨 유료페이지에 표출된 기사입니다.South Korea’s E.CIS Cosmetic garners strong interest from domestic capital market. As the company’s initial public offering (IPO) doesn’t go as planned, financial investors (FIs) including private equity firms are preparing to acquire its shares.
According to industry sources on February 7, some FIs have started to assess E.CIS’ valuation as the company’s planned IPO fell through.
Established in 2015, E.CIS is an original equipment manufacturer, specializing in the production of premium facial masks and other skin and hair care products. The company produces main sheet-masks of Mediheal, the country’s biggest sheet-mask brand. According to the company’s separate financial statement, E.CIS’ sales grew to 105 billion won in 2018 from 61.3 billion won in 2016. Market estimates that orders from L&P Cosmetic (Mediheal) account for around 75 percent of E.CIS’ total sales.
On this account, market watchers have mixed views on whether the company will be able to maintain its captive supplier position in case of a change in the shareholder structure. A son of Kwon Oh-sub, CEO of L&P Cosmetic, is a major shareholder of E.CIS with a 11.7 percent stake. Market watchers widely see they are related companies.
“Market watchers have constantly pointed out that E.CIS will have to diversify its source of sales to maintain its stable growth,” said an IB industry insider.
On the contrary, some view that E.CIS will continue to improve its earnings thanks to its technical skills. As a result of increasing its vendors in the U.S., E.CIS was awarded the $5 million Export Tower from Korea International Trade Association (KITA) in 2018.
It is said that although the company has continuously increased its brand awareness at home and abroad, the failure of its IPO has kept the company under pressure. E.CIS applied for a preliminary review for listing to the Korea Exchange (KRX) in July of 2019, but it withdrew its application next month.
In the meanwhile, E.CIS has announced publicly that it will proceed with its plan to be listed on the KRX's development board, Kosdaq. “Our initial plan for the IPO has not been changed,” said an E.CIS official.
(By reporter Rho Arrum)
최신뉴스 in 전체기사
- 오름테라퓨틱, 'ADC+TPD' 항암제 임상 1상 진입
- 블루베리NFT-현대백화점, 팝업스토어 이벤트 마무리
- '3000억 베팅' NVC파트너스, 메쉬코리아 공동 경영 나선다
- SK에코플랜트의 자회사 'TMI'
- [건설사 시공능력 점검]한신공영, 시평순위 주춤…선별수주 전략 선회
- [건설사 시공능력 점검]동양건설산업, 9년만에 50위권 첫 진입
- [thebell interview]비즈니스캔버스 "즐겁게 함께 일하는 문화 확산 기여하겠다"
- 퀀텀벤처스, 'LP지분 유동화' 펀드 만든다
- CJ CGV, 영구CB 발행 불구 신용도 방어 힘겹다
- [IPO 모니터]서울보증 주관사 경쟁, 은행계 하우스가 거머쥐나
Translated by Kim So-in 의 다른 기사 보기
더벨 서비스 문의
02-724-4102유료 서비스 안내